Design Therapeutics, Inc. (DSGN) shares fell 25.72 percent to $10.68, down $3.69 on Monday, despite the company reporting positive biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 for Friedreich ataxia.
The stock is currently trading at $10.68, compared with a previous close of $14.37 on the Nasdaq. It opened at $15.94 and traded between $10.45 and $16.95 during the session, with volume reaching 3.81 million shares, well above the average daily volume of 397,863 shares.
The company said DT-216P2 increased frataxin expression and produced dose-dependent clinical improvements. In the highest dose cohort, patients showed an average 6.4-point improvement in the modified Friedreich's Ataxia Rating Scale after four weeks of treatment, along with gains in stability and fatigue scores.
Design Therapeutics shares have traded between $3.31 and $17.25 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.